Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Nagels, Helen E ^a   Rishworth, Josephine R ^a   Siristatidis, Charalampos S ^b   Kroon, Ben ^c,d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ATHENS   (Greece)

^c Queensland Fertility Group   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PLACEBO; PRASTERONE; TESTOSTERONE; ANDROGEN;

BIRTH RATE; DRUG EFFICACY; DRUG SAFETY; FEMALE SUBFERTILITY; HUMAN; INFERTILITY THERAPY; LIVE BIRTH; MULTIPLE PREGNANCY; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; ABORTION, SPONTANEOUS; ADULT; FEMALE; INFERTILITY, FEMALE; META ANALYSIS; PREGNANCY;

ABORTION, SPONTANEOUS; ADULT; ANDROGENS; DEHYDROEPIANDROSTERONE; ESTRADIOL; FEMALE; HUMANS; INFERTILITY, FEMALE; LIVE BIRTH; PREGNANCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCTIVE TECHNIQUES, ASSISTED; TESTOSTERONE;

EID: 84956474692     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009749.pub2     Document Type: Review

References (84)

1. Artini PG, Simi G, Ruggiero M, Pinelli S, Di Berardino OM, Papini F, et al. DHEA supplementation improves follicular microenvironment in poor responder patients. Gynecological Endocrinology 2012;28(9):669-73.
2. Divita AE, Kanzepolsky LS, Notrica JA, Neuspiller FD, Polak de Fried E. Does dehidroepiandrosterone sulfate (Dheas) co-treatment improve art outcome? A prospective, randomized, double-blind placebo-controlled trial. Fertility and Sterility 2003;80 Suppl 3:S111-2.
3. Evans J. A randomised, double blinded, placebo controlled, single centre trial comparing dehydroepiandrosterone (DHEA) and placebo in the treatment of women with resistant ovaries prior to in vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI). RCOG World Congress; 2013 June 24-26; Liverpool, UK. BJOG. 2013; Vol. EP2.93:225.
4. Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F, et al. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Human Reproduction 2009;24(2):349-59.
5. Jindal A, Singh R. A prospective randomised controlled study on the role of dehydroepiandrosterone (DHEA) on improving ovarian response in known poor responders in previous failed IVF-ICSI cycles. Human Reproduction. 2014; Vol. 29:Supp 1, i14.
6. Kara M, Aydin T, Aran T, Turktekin N, Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2014;173:63-5.
7. Kara M, Aydin T, Aran T, Turktekin N, Ozdemir B. Is dehydroepiandrosterone (DHEA) supplementation really effective on IVF-ICSI outcome in patients with poor ovarian reserve?. Fertility and Sterility 2013;100(3, Supplement):S518.
8. Kim CH, Ahn JW, Nah HY, Kim SH, Chae HD, Kang BM. Ovarian features after 2 weeks, 3 weeks and 4 weeks transdermal testosterone gel treatment and their associated effect on IVF/ICSI outcome in low responders. Fertility and Sterility 2010;94(4 Suppl):S155-6.
9. Kim CH, Howles CM, Lee HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertility and Sterility 2011;95(2):679-83.
10. Díaz C, Pellicer A, Marzal A. Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders (FOLLPRIM). https://clinicaltrials.gov/ct2/show/NCT01310647 (accessed 21 May 2014). [: NCT01310647]
11. Díaz C, Pellicer A, Marzal A. Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders (FOLLPRIM). personal correspondence 2014.
12. Marzal A, Monterde M, Díaz-García C, Gómez R, Rubio JM. Antral follicle priming prior to ICSI in confirmed low responders: a randomized clinical trial (FOLLPRIM). Human Reproduction 2014;29(Supp 1):i25.
13. Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J, Wolf JP, Hugues JN. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique--a prospective, randomized, double-blind study. Human Reproduction 2006;21(5):1204-11.
14. Moawad M, Shaeer M. Long-term androgen priming by use of dehydroepiandrosterone (DHEA) improves IVF outcome in poor-responder patients. A randomized controlled study. Middle East Fertility Society Journal 2012;17(4):268-74.
15. Tartagni M, De Pergola G, Damiani GR, Pellegrino A, Baldini D, Tartagni MV, et al. Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program. Minerva Ginecologica 2015;67(1):7-12.
16. Tartagni M, Cicinelli MV, Baldini D, Tartagni MV, Alrasheed H, DeSalvia MA, et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reproductive Biology and Endocrinology 2015;13:13-8. [DOI: 10.1186/s12958-015-0014-3]
17. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Human Reproduction 2010;25(10):2496-500.
18. Yeung TWY, Li RHW, Lee VCY, Chai J, Ng EHY, Ho PC. A randomized double-blinded placebo-controlled trial on the effect of 16 weeks of dehydroepiandrosterone (DHEA) on ovarian reserve markers and IVF outcomes in normal responders. Fertility and Sterility 2013;100(3, Supplement):S114.
19. Yeung TWY, Chai J, Li RHW, Lee VCY, Ho PC, Ng EHY. A randomized double-blinded placebo-controlled trial on the effect of 16 weeks of dehydroepiandrosterone (DHEA) on ovarian reserve markers and IVF outcomes in poor responders. Fertility and Sterility 2013;100(3, Suppl):S159-60.
20. Yeung TWY, Chai J, Li RHW, Lee VCY, Ho PC, Ng EHY. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertility and Sterility 2014;102(1):108-15.e1. [DOI: 10.1016/j.fertnstert.2014.03.044]
21. Zhang HH, Xu PY, Wu J, Zou WW, Xu XM, Cao XY, et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. Journal of Ovarian Research 2014;7:93.
22. Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Human Reproduction 2006;21(7):1884-93.
23. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Human Reproduction 2006;21(11):2845-9.
24. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. Journal of Assisted Reproduction and Genetics 2007;24(12):629-34.
25. Barad D. A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF). https://clinicaltrials.gov/ct2/show/NCT00419913 (accessed 12 March 2015). [: NCT00419913]
26. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction 2000;15(10):2129-32.
27. de los Santos MJ, García-Laez V, Beltrán D, Labarta E, Zuzuarregui JL, Alamá P, et al. The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: is it hypoandrogenic?. Human Reproduction 2013;28(1):224-9.
28. Fábregues F. Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone. https://clinicaltrials.gov/ct2/show/NCT01291212 (accessed 12 March 2015). [: NCT01291212]
29. Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecological Endocrinology 2013;29(10):940-3.
30. Gleicher N, Kim A, Weghofer A, Shohat-Ta A, Lazzaroni E, Lee HJ, et al. Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). Journal of Assisted Reproduction and Genetics 2013;30(1):49-62.
31. Hyman JH, Margalioth EJ, Rabinowitz R, Tsafrir A, Algur N, Eldar-Geva T. Dehydroepiandrosterone (DHEA) supplementation for poor responders - how does it work?. Fertility and Sterility 2010;94(4, Supplement):S86.
32. Hyman JH, Margalioth EJ, Rabinowitz R, Tsafrir A, Gal M, Alerhand S, et al. DHEA supplementation may improve IVF outcome in poor responders: a proposed mechanism. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2013;168(1):49-53.
33. Monterde M, Gomez R, Marzal A, Vega O, Rubio J, Diaz-Garcia C, et al. Molecular expression of androgen and FSH receptors after follicular priming prior to ICSI cycles - an interim analysis of the IFILL-PRIMI randomised controlled trial. Human Reproduction 2013;28(Suppl 1):i342.
34. Motta EL, Rossi LM, Fernandes TR, Massaguer AA, Fassolas G, Serafini P. The use of DHEA in poor responders does not improve IVF outcomes: insights of a pilot study. Fertility and Sterility 2006;86(Suppl 2):S428.
35. Singh N, Zangmo R, Kumar S, Roy KK, Sharma JB, Malhotra N, et al. A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve. Gynecological Endocrinology 2013;29(11):989-92.
36. Sipe CS, Thomas MR, Stegmann BJ, Van Voorhis BJ. Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles. Human Reproduction 2010;25(3):690-6.
37. Sönmezer M, Ozmen B, Çil AP, Ozkavukçu S, Taşçi T, Olmuş H, et al. Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reproductive BioMedicine Online 2009;19(4):508-13.
38. Yeung TW, Li RH, Lee VC, Ho PC, Ng EH. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. Journal of Clinical Endocrinology and Metabolism 2013;98(1):380-8.
39. Study of Oral Dehydroepiandrosterone (DHEA) to Treat Previously Unexplained Infertility. Ongoing study March 2008.
40. A Randomized Double Blind Control Trial of Transdermal Testosterone Supplementation vs Placebo on Follicular Development and Atresia, Oocyte and Embryo Quality Among Women With Diminished Ovarian Reserve Undergoing in Vitro Fertilization. Ongoing study July 2012End date: December 2014.
41. Jayaprakasan K, Narkwichean A, Maalouf WE, Campbell BK. Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): A proof of principle randomised controlled trial protocol. BMJ Open 2014;4:10.
42. Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF. Ongoing study October 2013Estimated primary completion date: October 2014 (final data collection date for primary outcome measure).
43. DHEA Supplementation for Low Ovarian Response IVF Patients. Ongoing study Jan 2008.
44. Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients. Ongoing study February 2012.
45. Prospective Randomized Trial on the Effect of DHEA Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and Pregnancy Outcome.. Ongoing study April 2014.
46. Akhtar MA, Sur S, Raine-Fenning N, Jayaprakasan K, Thornton JG, Quenby S. Heparin for assisted reproduction. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD009452.pub2]
47. Bosdou JK, Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Zepiridis l, et al. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Human Reproduction Update 2012;18(2):127-45.
48. Buvat J. Androgen therapy with dehydroepiandrosterone. World Journal of Urology 2003;21(5):346-55.
49. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertility and Sterility 1998;70(1):107-10.
50. Cheong YC, Dix S, Hung Yu Ng E, Ledger WL, Farquhar C. Acupuncture and assisted reproductive technology. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD006920.pub3]
51. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 2010;63(8):834-40.
52. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. Journal of Clincal Endocrinology and Metabolism 2005;90(7):3847-53.
53. Fouany MR, Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve?. Journal of Assisted Reproduction and Genetics 2013;30(9):1239-44.
54. Frattarelli JL, Peterson EH. Effect of androgen levels on in vitro fertilization cycles. Fertility and Sterility 2004;81(6):1713-4.
55. Garcia-Velasco JA, Moreno L, Pacheco A, Guillén A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertility and Sterility 2005;84(1):82-7.
56. Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertility and Sterility 2001;76(2):241-8.
57. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reproductive Biology and Endocrinology 2009;7:108.
58. Gleicher N, Barad D. Dehydroepiandrosterone. In: Kovacs G editor(s). How to improve your ART success rates. Cambridge: Cambridge University Press, 2011:93-8.
59. Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?. Reproductive Biology and Endocrinology 2011;9:116.
60. Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J, Freundl G. Definition and prevalence of subfertility and infertility. Human Reproduction 2005;20(5):1144-7.
61. González-Comadran M, Durán M, Solà I, Fábregues F, Carreras R, Checa MA. Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. Reproductive BioMedicine Online 2012;25(5):450-9.
62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
63. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
64. Horie K, Takakura K, Imai K, Liao S, Mori T. Immunohistochemical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium. Human Reproduction 1992;7(10):1461-6.
65. Karp G, Bentov Y, Masalha R, Ifergane G. Onset of late posttraumatic seizure after dehydroepiandrosterone treatment. Fertility and Sterility 2009;91(3):931.e1-2.
66. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertility and Sterility 2009;91(2):644-6.
67. Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Current Opinion in Obstetrics and Gynaecology 2009;21(4):306-8.
68. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. Journal of Clinical Endocrinology and Metabolism 1994;78(6):1360-7.
69. Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Møllgård K, Wreford Andersen E, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Molecular Human Reproduction 2011;17(1):63-70.
70. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
71. Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and thecal cells. Journal of Clinical Endocrinology & Metabolism 1968;28(3):355-8.
72. Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Molecular Endocrinology 2010;24(7):1393-403.
73. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Human Reproduction 2002;17(10):2573-9.
74. Siristatidis CS, Dodd SR, Drakeley AJ. Aspirin for in vitro fertilisation. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD004832.pub3]
75. Somboonporn W, Davis SR, Seif MW, Bell RJ. Testosterone for peri- and postmenopausal women. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004509.pub2]
76. Sunkara SK, Pundir J, Khalaf Y. Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis. Reproductive BioMedicine Online 2011;22(6):545-55.
77. Toner JP. Progress we can be proud of: U.S. trends in assisted reproduction over the first 20 years. Fertility and Sterility 2002;78(5):943-50.
78. Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biology of Reproduction 1999;61(2):353-7.
79. Venetis CA, Bosdou J, Kolibianakis E, Toulis K, Goulis D, Tarlatzis BC. Improved probability of pregnancy with transdermal testosterone pretreatment in poor responders treated with GnRH analogues and gonadotrophins for in-vitro fertilization: a meta-analysis. Fertility and Sterility 2011;96(3):S56.
80. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. Journal of Clinical Endocrinology and Metabolism 1998;83(7):2479-85.
81. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. Journal of Clinical Endocrinology and Metabolism 1999;84(8):2951-6.
82. Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope?. Human Reproduction 2011;26(8):1941-4.
83. Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertility and Sterility 2009;92(5):1520-4.
84. Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) in women undergoing assisted reproduction. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD009749]